shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)

    RFA-CA-24-006

    National Institutes of Health

    Opening date 16 Oct 2023, 12:00AM

    Closing date 4 Dec 2024, 12:00AM

    Funding Opportunity Number: RFA-CA-24-006

    Opportunity Category: Discretionary

    CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research,93.395 -- Cancer Treatment Research,93.399 -- Cancer Control

    Cost Sharing or Matching Requirement: No

    Posted Date: Oct 16, 2023 12:00:00 AM EDT

    Closing Date: Dec 04, 2024 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Independent school districts,Native American tribal governments (Federally recognized),For profit organizations other than small businesses,Small businesses,State governments,Public housing authorities/Indian housing authorities,Others (see text field entitled "Additional Information on Eligibility" for clarification),City or township governments,Public and State controlled institutions of higher education,Special district governments,Private institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled Investigation of the Transmission of KSHV (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL) and KSHV inflammatory cytokine syndrome (KICS) or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people who are already infected with KSHV. Research areas could include, but are not limited to: (1) Identification and evaluation of KSHV structural and non-structural targets for a potential KSHV vaccine; (2) Development of animal models to study a prototype KSHV vaccine or vaccines; (3) Development and testing of a candidate KSHV vaccine or vaccines; (4) Studies to assess how the efficacy of a promising KSHV vaccine can be optimized for PWH; (5) Research to better define the initial steps of infection with KSHV and the primary means of person-to-person transmission in different populations that can be targeted with a vaccine; and (6) Optimization and/or standardization of KSHV detection methods.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept